C G H Dahlöf

Summary

Affiliation: Gothenburg Migraine Clinic
Country: Sweden

Publications

  1. ncbi Cutaneous allodynia and migraine: another view
    Carl Dahlof
    Gothenburg Migraine Clinic, c o Läkarhuset, Södra vägen 27, S 411 35 Gothenburg, Sweden
    Curr Pain Headache Rep 10:231-8. 2006
  2. ncbi Rizatriptan: a new 5-HT1B/1D receptor agonist for the treatment of migraine
    C Dahlof
    Gothenburg Migraine Clinic, Sociala Huset, Uppg D, S 411 17, Gothenburg, Sweden
    Expert Opin Investig Drugs 8:671-85. 1999
  3. pmc The impact of migraine prevention on daily activities: a longitudinal and responder analysis from three topiramate placebo-controlled clinical trials
    Carl Dahlof
    Gothenburg Migraine Clinic, c o Läkarhuset, Södra vägen 27, S 41135 Gothenburg, Sweden
    Health Qual Life Outcomes 5:56. 2007
  4. ncbi [Migraine from a female perspective]
    Carl Dahlof
    Institutionen för neurovetenskap och fysiologi, Sahlgrenska akademin, Göteborgs Universitet
    Lakartidningen 104:1812-4. 2007
  5. ncbi [Background and treatment of migraine disease]
    Carl Dahlof
    Institutionen för neurovetenskap och fysiologi, Sahlgrenska akademin, Göteborgs Universitet
    Lakartidningen 104:1806-10. 2007
  6. ncbi Efficacy, speed of action and tolerability of almotriptan in the acute treatment of migraine: pooled individual patient data from four randomized, double-blind, placebo-controlled clinical trials
    C G Dahlof
    Institute of Clinical Neuroscience, Gothenburg Migraine Clinic, Gothenburg, Sweden
    Cephalalgia 26:400-8. 2006
  7. ncbi Infrequent or non-response to oral sumatriptan does not predict response to other triptans--review of four trials
    C G H Dahlöf
    Gothenburg Migraine Clinic, Gothenburg, Sweden
    Cephalalgia 26:98-106. 2006
  8. ncbi Withdrawal therapy improves chronic daily headache associated with long-term misuse of headache medication: a retrospective study
    P Linton-Dahlöf
    Gothenburg Migraine Clinic, Goteborg, Sweden
    Cephalalgia 20:658-62. 2000
  9. ncbi Non-oral formulations of triptans and their use in acute migraine
    Carl G H Dahlöf
    Gothenburg Migraine Clinic, c o Läkarhuset, Södra vägen 27, S 411 35 Gothenburg, Sweden
    Curr Pain Headache Rep 9:206-12. 2005
  10. ncbi [Can migraine cause subclinical brain lesions? A Dutch study shows a connection--but more research is required]
    Carl G H Dahlöf
    Migränklinik Göteborg, Institutionen för klinisk neurovetenskap, Sahlgrenska Universitetssjukhuset, Goteborg, Sweden
    Lakartidningen 101:3782, 3785-6, 3788. 2004

Collaborators

Detail Information

Publications18

  1. ncbi Cutaneous allodynia and migraine: another view
    Carl Dahlof
    Gothenburg Migraine Clinic, c o Läkarhuset, Södra vägen 27, S 411 35 Gothenburg, Sweden
    Curr Pain Headache Rep 10:231-8. 2006
    ..It also will reduce the overall proportion of migraine attacks or migraineurs not responding to triptan treatment. Notwithstanding, the recommendation of early treatment during the migraine attack when the pain is mild remains valid...
  2. ncbi Rizatriptan: a new 5-HT1B/1D receptor agonist for the treatment of migraine
    C Dahlof
    Gothenburg Migraine Clinic, Sociala Huset, Uppg D, S 411 17, Gothenburg, Sweden
    Expert Opin Investig Drugs 8:671-85. 1999
    ..In summary, rizatriptan is an effective and well-tolerated acute treatment for migraine, which may offer some advantages over oral sumatriptan...
  3. pmc The impact of migraine prevention on daily activities: a longitudinal and responder analysis from three topiramate placebo-controlled clinical trials
    Carl Dahlof
    Gothenburg Migraine Clinic, c o Läkarhuset, Södra vägen 27, S 41135 Gothenburg, Sweden
    Health Qual Life Outcomes 5:56. 2007
    ..001). The MSQ measures how much migraine limits/interrupts daily performance. Pooled analyses of pivotal trial data were conducted to further assess how topiramate 100 mg/d affects daily activities and patient functioning...
  4. ncbi [Migraine from a female perspective]
    Carl Dahlof
    Institutionen för neurovetenskap och fysiologi, Sahlgrenska akademin, Göteborgs Universitet
    Lakartidningen 104:1812-4. 2007
  5. ncbi [Background and treatment of migraine disease]
    Carl Dahlof
    Institutionen för neurovetenskap och fysiologi, Sahlgrenska akademin, Göteborgs Universitet
    Lakartidningen 104:1806-10. 2007
  6. ncbi Efficacy, speed of action and tolerability of almotriptan in the acute treatment of migraine: pooled individual patient data from four randomized, double-blind, placebo-controlled clinical trials
    C G Dahlof
    Institute of Clinical Neuroscience, Gothenburg Migraine Clinic, Gothenburg, Sweden
    Cephalalgia 26:400-8. 2006
    ..5 mg was not significantly different from that of placebo. This meta-analysis confirms the findings of individual clinical trials, while demonstrating for the first time, significant pain-free efficacy at 30 min compared with placebo...
  7. ncbi Infrequent or non-response to oral sumatriptan does not predict response to other triptans--review of four trials
    C G H Dahlöf
    Gothenburg Migraine Clinic, Gothenburg, Sweden
    Cephalalgia 26:98-106. 2006
    ..A review of the available evidence suggests that almotriptan may be one of the most appropriate choices for an alternative triptan...
  8. ncbi Withdrawal therapy improves chronic daily headache associated with long-term misuse of headache medication: a retrospective study
    P Linton-Dahlöf
    Gothenburg Migraine Clinic, Goteborg, Sweden
    Cephalalgia 20:658-62. 2000
    ....
  9. ncbi Non-oral formulations of triptans and their use in acute migraine
    Carl G H Dahlöf
    Gothenburg Migraine Clinic, c o Läkarhuset, Södra vägen 27, S 411 35 Gothenburg, Sweden
    Curr Pain Headache Rep 9:206-12. 2005
    ..Parenteral administration of a triptan is more likely to provide relief of symptoms, even when it is used later in the course of the migraine attack...
  10. ncbi [Can migraine cause subclinical brain lesions? A Dutch study shows a connection--but more research is required]
    Carl G H Dahlöf
    Migränklinik Göteborg, Institutionen för klinisk neurovetenskap, Sahlgrenska Universitetssjukhuset, Goteborg, Sweden
    Lakartidningen 101:3782, 3785-6, 3788. 2004
    ....
  11. ncbi Sumatriptan: pharmacological basis and clinical results
    C G Dahlof
    Gothenburg Migraine Clinic, Gothenburg, Sweden
    Curr Med Res Opin 17:s35-45. 2001
    ....
  12. ncbi Integrating the triptans into clinical practice
    Carl Dahlof
    Institute of Clinical Neuroscience, Gothenburg Migraine Clinic, Sociala Huset, Uppgang D, S 41117 Gothenburg, Sweden
    Curr Opin Neurol 15:317-22. 2002
    ..Despite these barriers to good efficacy and high reliability, the tablet is the most commonly used triptan formulation...
  13. ncbi [Type of primary headache can be diagnosed with the help of careful anamnesis. An account of and comments to a comprehensive review article]
    Carl Dahlof
    Migränklinik Göteborg, Sociala Huset, Goteborg
    Lakartidningen 99:270-5. 2002
  14. ncbi Dose finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine
    C Dahlof
    Gothenburg Migraine Clinic, Gothenburg, Sweden
    Neurology 57:1811-7. 2001
    ..To assess the efficacy and tolerability of oral almotriptan, a selective serotonin receptor (5-HT1B/1D) agonist, when used at different doses in the treatment of acute migraine...
  15. ncbi One-year prevalence of migraine in Sweden: a population-based study in adults
    C Dahlof
    Gothenburg Migraine Clinic, Goteborg, Sweden
    Cephalalgia 21:664-71. 2001
    ..An extension of the time window from 4 to 72 h may be reasonable both from a pragmatic and from a rational clinical point of view...
  16. doi Efficacy and safety of tonabersat, a gap-junction modulator, in the acute treatment of migraine: a double-blind, parallel-group, randomized study
    C G H Dahlöf
    Gothenburg Migraine Clinic, Gothenburg, Sweden
    Cephalalgia 29:7-16. 2009
    ..The lack of efficacy may be a function of the slow absorption of tonabersat. As a consequence of slow absorption, daily administration of tonabersat as prophylaxis for migraine attacks is under investigation in ongoing studies...
  17. ncbi [Is migraine a progressive cerebral disease?]
    C G H Dahlöf
    Clínica de la Migraña, Gotemburgo, Sweden
    Neurologia 20:356-65. 2005
    ....
  18. ncbi Sumatriptan (5-HT1B/1D-agonist) causes a transient allodynia
    M Linde
    Gothenburg Migraine Clinic, Gothenburg, Sweden
    Cephalalgia 24:1057-66. 2004
    ..This could explain at least some of the temporary sensory side-effects of triptans and warrants consideration in the interpretation of studies on migraine-induced allodynia...